Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a long non-coding natural antisense transcript that overlaps the serum response factor (SRF) gene. Antisense transcripts are widespread in both yeast and human genomes and act by mechanisms including transcriptional interference, RNA masking, double-stranded RNA formation, and chromatin modification. These processes can modulate the stability and processing of the sense mRNA, generally dampening its expression or altering transcript dynamics rather than encoding functional proteins. Antisense to SRF may regulate SRF expression epigenetically; however, there is no evidence that this transcript is a validated drug or therapeutic target, nor is it functionally classified as a receptor, enzyme, or classical target class. Furthermore, the identifier ENSG00000307823 does not map to a canonical Ensembl gene, implying a possible annotation, database, or nomenclature issue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to serum response factor.